This content is in French.
High-grade astrocytoma: combining two treatments opens a new therapeutic avenue
9 mars 2026
By Elodie Vaz | Published on March 9, 2026 | 3 min readHigh-grade astrocytoma, which includes glioblastoma, is among the most aggressive brain tumors. Its rapid growth and strong tendency to recur after surgical resection make it a disease with a poor prognosis. In the event of recurrence, median survival is generally only four to five months. While immune checkpoint inhibitors have transformed th
By Elodie Vaz | Published on March 9, 2026 | 3 min read
High-grade astrocytoma, which includes glioblastoma, is among the most aggressive brain tumors. Its rapid growth and strong tendency to recur after surgical resection make it a disease with a poor prognosis. In the event of recurrence, median survival is generally only four to five months.
While immune checkpoint inhibitors have transformed the management of many solid tumors by reactivating T lymphocytes against tumor cells, their effectiveness remains limited in brain tumors. The main reason is the blood–brain barrier.
High-grade astrocytoma, which includes glioblastoma, is among the most aggressive brain tumors. Its rapid growth and strong tendency to recur after surgical resection make it a disease with a poor prognosis. In the event of recurrence, median survival is generally only four to five months.
While immune checkpoint inhibitors have transformed the management of many solid tumors by reactivating T lymphocytes against tumor cells, their effectiveness remains limited in brain tumors. The main reason is the blood–brain barrier.
Sign in to read the rest
Reserved for healthcare professionals, free registration.
Scientific reference
New treatment may dramatically improve survival for those with deadly brain cancer
View the source
